021-51111890
购物车（）
sales@molnova.cn
Burosumab
CAS No. 1610833-03-8
Burosumab ( —— )
产品货号. M36902 CAS No. 1610833-03-8
Burosumab 是一种人 FGF23 中和抗体，可用于 X 连锁低磷血症 (XLH) 和肿瘤导致的骨软化的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥4484 | 有现货 |
|
| 10MG | ￥6261 | 有现货 |
|
| 25MG | ￥9095 | 有现货 |
|
| 50MG | ￥11997 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Burosumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Burosumab 是一种人 FGF23 中和抗体，可用于 X 连锁低磷血症 (XLH) 和肿瘤导致的骨软化的研究。
-
产品描述Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number1610833-03-8
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne). 2020 May 28;11:338.?
产品手册
关联产品
-
Endixaprine
Endixaprine (SR 41378) is a small molecule compound used to treat neurological disorders and may be used to study anxiety disorders and epilepsy.
-
Calcitonin Gene Rela...
Calcitonin Gene Related Peptide II, human
-
(±)8(9)-EpETE
Eicosapentaenoic acid is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. The major product of this epoxygenase pathway, (±)17(18)-EpETE , relaxes vascular and airway smooth muscle by activating large conductance Ca2+-activated K+ (BKCa) channels by directly interacting with BKα channel subunits. (±)8(9)-EpETE is an epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo. The biological actions and physiological effects of this epoxide remain to be determined.
